S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Cyclerion Therapeutics Stock Forecast, Price & News

+0.02 (+1.46%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
73,515 shs
Average Volume
208,510 shs
Market Capitalization
$60.21 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cyclerion Therapeutics logo

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.30 million
Book Value
$1.75 per share


Net Income
$-77.80 million
Net Margins
Pretax Margin




Free Float
Market Cap
$60.21 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.02 out of 5 stars

Medical Sector

592nd out of 1,124 stocks

Pharmaceutical Preparations Industry

288th out of 542 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

Is Cyclerion Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cyclerion Therapeutics stock.
View analyst ratings for Cyclerion Therapeutics
or view top-rated stocks.

How has Cyclerion Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYCN shares have decreased by 52.1% and is now trading at $1.39.
View which stocks have been most impacted by COVID-19

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 624,800 shares, a decrease of 59.4% from the December 15th total of 1,540,000 shares. Based on an average daily volume of 403,000 shares, the short-interest ratio is currently 1.6 days.
View Cyclerion Therapeutics' Short Interest

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cyclerion Therapeutics

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.26) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.09. The business had revenue of $0.35 million for the quarter, compared to analysts' expectations of $3 million. Cyclerion Therapeutics had a negative trailing twelve-month return on equity of 104.73% and a negative net margin of 1,696.27%.
View Cyclerion Therapeutics' earnings history

What price target have analysts set for CYCN?

3 Wall Street analysts have issued 12 month price objectives for Cyclerion Therapeutics' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Cyclerion Therapeutics' stock price to reach $11.67 in the next year. This suggests a possible upside of 739.3% from the stock's current price.
View analysts' price targets for Cyclerion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cyclerion Therapeutics' key executives?

Cyclerion Therapeutics' management team includes the following people:
  • Peter M. Hecht, CEO, CFO, Director & Chief Accounting Officer (LinkedIn Profile)
  • Cheryl Gault, Chief Operating Officer
  • Andreas Eugen Busch, Chief Scientific Officer
  • Kevin Durfee, Vice President-Information Technology & Facilities
  • G. Todd Milne, Vice President-Corporate Development

What other stocks do shareholders of Cyclerion Therapeutics own?

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $1.39.

How much money does Cyclerion Therapeutics make?

Cyclerion Therapeutics has a market capitalization of $60.21 million and generates $2.30 million in revenue each year.

How many employees does Cyclerion Therapeutics have?

Cyclerion Therapeutics employs 51 workers across the globe.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

Where are Cyclerion Therapeutics' headquarters?

Cyclerion Therapeutics is headquartered at 301 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at (857) 327-8778 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.